The Safety and Efficacy of Low‐Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders
- 23 February 2018
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 38 (3) , 382-389
Abstract
Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off‐label, complimentary, or alternative medicines to gain relief from symptoms. Low‐dose naltrexone has been used off‐label for treatment of pain and inflammation in multiple sclerosis, Crohn's disease, fibromyalgia, and other diseases. Naltrexone is a mu‐opioid receptor antagonist indicated by the U.S. Food and Drug Administration for opioid and alcohol dependence. It is hypothesized that lower than standard doses of naltrexone inhibit cellular proliferation of T and B cells and block Toll‐like receptor 4, resulting in an analgesic and antiinflammatory effect. It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low‐dose naltrexone for use in chronic pain and inflammatory conditions. Currently, evidence supports the safety and tolerability of low‐dose naltrexone in multiple sclerosis, fibromyalgia, and Crohn's disease. Fewer studies support the efficacy of low‐dose naltrexone, with most of these focusing on subjective measures such as quality of life or self‐reported pain. These studies do demonstrate that low‐dose naltrexone has subjective benefits over placebo, but evidence for more objective measures is limited. However, further randomized controlled trials are needed to determine the efficacy of low‐dose naltrexone due to insufficient evidence supporting its use in these disease states. This review provides practitioners with the extent of low‐dose naltrexone evidence so that they can be cognizant of situations where it may not be the most appropriate therapy.Keywords
This publication has 48 references indexed in Scilit:
- Low-Dose Naltrexone for Pruritus in Systemic SclerosisInternational Journal of Rheumatology, 2011
- Modulation of the opioid growth factor ([Met5]‐enkephalin)–opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neckHead & Neck, 2011
- Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trialThe Lancet Neurology, 2011
- Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled TrialDigestive Diseases and Sciences, 2011
- Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosisBrain Research, 2011
- Evidence that opioids may have toll-like receptor 4 and MD-2 effectsBrain, Behavior, and Immunity, 2010
- Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot StudyPain Medicine, 2009
- Opioids and the treatment of chronic pain: Controversies, current status, and future directions.Experimental and Clinical Psychopharmacology, 2008
- Non‐stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll‐like receptor 4 (TLR4)European Journal of Neuroscience, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007